Clinical Trial Update: Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update from Novo Nordisk reports completion of a study evaluating how the fixed-ratio CagriSema combination, along with semaglutide and c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)
• Cagrilintide (cagrilintide)
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED